Skip to main content
    4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.29
    -0.94 (-7.69%)

    Market Cap: $689.52M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    4D Molecular Therapeutics Inc (FDMT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to 4D Molecular Therapeutics are Design Therapeutics (DSGN), DBV Technologies (DBVT) and Taysha Gene Therapies (TSHA). By market cap, 4D Molecular Therapeutics ranks 6th of the 13 companies on this page; Taysha Gene Therapies (TSHA) is the largest at $1.34B.

    Peer Comparison

    FDMT's ROIC of -46.4% is below the peer median of -38.1%, and its revenue growth of 4506.0% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    4D Molecular Therapeutics (FDMT)$689.52MN/A8.5x-208.6%-46.4%4506.0%0.00%
    Design Therapeutics Inc (DSGN)$670.46MN/AN/A0.0%N/A0.0%0.00%
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Taysha Gene Therapies Inc (TSHA)$1.34BN/A300.6x0.0%-32.8%171.3%0.00%
    DiaMedica Therapeutics Inc (DMAC)$474.29MN/AN/A0.0%N/A0.0%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Alpha Tau Medical Ltd (DRTS)$1.24BN/AN/A0.0%-176.9%0.0%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Solid Biosciences LLC (SLDB)$763.42MN/AN/A0.0%N/A-100.0%0.00%
    Candel Therapeutics Inc (CADL)$486.37MN/AN/A0.0%-43.5%0.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Adlai Nortye Ltd. American Depositary Shares (ANL)$683.26MN/A8.1x-124.8%-7.3%178.1%0.00%
    Peer median$676.86M95.1x8.3x0.0%-38.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to 4D Molecular Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Design Therapeutics Inc (DSGN)
    Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.
    DSGN competitors
    DBV Technologies (DBVT)
    DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products.
    DBVT competitors
    Taysha Gene Therapies Inc (TSHA)
    Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies...
    TSHA competitors
    DiaMedica Therapeutics Inc (DMAC)
    DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
    DMAC competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Alpha Tau Medical Ltd (DRTS)
    Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development...
    DRTS competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Solid Biosciences LLC (SLDB)
    Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States.
    SLDB competitors
    Candel Therapeutics Inc (CADL)
    Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform...
    CADL competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Adlai Nortye Ltd. American Depositary Shares (ANL)
    Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.

    Frequently Asked Questions About FDMT

    Who are 4D Molecular Therapeutics' main competitors?

    The companies most similar to 4D Molecular Therapeutics include Design Therapeutics (DSGN), DBV Technologies (DBVT), Taysha Gene Therapies (TSHA), DiaMedica Therapeutics (DMAC) and Neurogene (NGNE), listed from the closest match.

    Who is 4D Molecular Therapeutics' biggest competitor?

    Taysha Gene Therapies (TSHA) is the largest of the similar companies at $1.34B; Design Therapeutics (DSGN) is the closest match by business profile, size, sector and industry.

    How does FDMT stock compare with its competitors?

    FDMT's P/S is 8.5x against a peer median of 8.3x; its net margin is -208.6% against a peer median of 0.0%.

    Which of 4D Molecular Therapeutics' competitors pays a higher dividend?

    4D Molecular Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is 4D Molecular Therapeutics bigger than its competitors?

    No. 4D Molecular Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Taysha Gene Therapies (TSHA) at $1.34B.